c-MET Inhibition Reverses the Osimertinib Resistance in Lung Circulating Tumor Cell Clusters and Suppresses Metastasis
Abstract Background Circulating tumor cells (CTCs) serve as the “seeds” of tumor metastasis, and the clustering of CTCs is critically associated with tumor metastasis and the mortality of lung cancer patients. Inhibiting the survival of CTC clusters represents a pivotal strategy for anti-lung cancer...
Saved in:
| Main Authors: | Zhipeng Zhang, Xinyi Lu, Jianhui Tian, Jiaxuan Li, Shihui Liu, Jiajun Liu, Bin Luo, Jialiang Yao, Yao Liu, Yanhong Wang, Wang Yao, Yun Yang, Wenji Shangguan, Zujun Que |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Biological Procedures Online |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12575-025-00295-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fexofenadine Overcomes Osimertinib Resistance by Inhibiting c‐Met in Non‐Small Cell Lung Cancer
by: Kenneth K. W. To, et al.
Published: (2025-06-01) -
Copy number gain of MET gene with low level in a metastatic lung adenocarcinoma patient represents response to salvage treatment with savolitinib and osimertinib: a case report
by: Jian Wang, et al.
Published: (2025-04-01) -
The potential role of next-generation sequencing in identifying MET amplification and disclosing resistance mechanisms in NSCLC patients with osimertinib resistance
by: Xiao Xiao, et al.
Published: (2024-10-01) -
Anlotinib Plus Osimertinib in Osimertinib‐Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study
by: Yu Hua, et al.
Published: (2025-05-01) -
Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study
by: Jixian Li, et al.
Published: (2025-07-01)